PubMed Health⌕ Search

Biomedical subjects

I A Jaffe

Publications and source records attributed to I A Jaffe.

At least 19 recordsLinked to original sources
PubMed1997

Wegener's granulomatosis and ANCA syndromes.

The nervous system is involved in approximately 25% of patients with classical Wegener's granulomatosis. The spectrum of this disease has been broadened with the discovery of the anti-neutrophil cytoplasmic antibodies, which are found in diseases sharing many clinical features. The ANCA testing may indicate a common mode of pathogenesis. The definitive diagnostic marker is histological, and that forms the best guide to specific therapy.

Adrenal Cortex Hormones↗
PubMed1992

Cholesterol emboli neuropathy.

We report the clinical and pathologic features of a patient with peripheral neuropathy that was the first clinical expression of cholesterol emboli syndrome (CES). Biopsy of skeletal muscle and peripheral nerve revealed cholesterol clefts in lumens of small arteries, necrotizing arteritis, and severe degeneration of peripheral and intramuscular nerves. At autopsy, the peripheral nervous system was extensively affected by similar changes. We conclude that (1) peripheral neuropathy may be the initial manifestation of CES. Presumably, deposition of cholesterol leads to arteritis. (2) The underlying pathology of CES neuropathy is chronic axonal degeneration, possibly due to chronic ischemia of epineurial arteries. (3) Muscle biopsy is important in the antemortem diagnosis of CES. Nerve biopsy may show involvement of epineurial vessels. (4) CES may resemble polyarteritis nodosa clinically and pathologically. (5) CES may be under-recognized and should be included in the differential diagnosis of any neuropathy of uncertain cause, particularly when there is a history of vascular catheterization, or severe aortic atherosclerosis.

Aged↗
PubMed1992

New approaches to the management of rheumatoid arthritis.

The approach to the treatment of rheumatoid arthritis is currently undergoing fundamental change. The demonstration of erosions by magnetic resonance imaging early in the disease, when conventional radiographs only show soft tissue swelling, demands rapid intervention with more effective drugs. The increasing use of methotrexate earlier in the course of the disease is justified, in view of the favorable benefit/risk ratio. New experimental therapies, such as photopheresis, the fusion protein, DAB486 interleukin 2, FK 506, and monoclonal CD4+, may also be utilized earlier if their safety profiles permit. Conventional therapeutic regimens are being administered differently in an attempt to improve efficacy and safety.

Acquired Immunodeficiency Syndrome↗
PubMed1990

Combination therapy of rheumatoid arthritis--rationale and overview.

Currently available therapeutic agents for the treatment of rheumatoid arthritis are unsatisfactory for many patients, due either to inefficacy, loss of effectiveness with time, or toxicity. One approach is to study drugs in combination, at lower than usual dosages of each, in order to achieve greater efficacy with fewer adverse reactions. To aid in this review of published trials, the various combinations have been arbitrarily divided into combinations of cytotoxic (antiproliferative) drugs with each other, and combinations of noncytotoxic drugs. Of the noncytotoxic combinations, intramuscular gold with D-penicillamine appeared to offer the best results without increased side effects when compared to each one used alone. The most promising cytotoxic combination was methotrexate with azathioprine.

Antimalarials↗